This grant explores the hypothesis that methylation-directed inactivation of TSGs often implicated during early onset of disease exacerbates CRC progression, and that co-targeting dysregulated epigenetic regulators in CIMP-positive tumors will restore the critical function of TSGs and potentially lead to the development of chemoprevention. Furthermore, the methylation profiling offers an opportunity to improved stratification of CRC patients.
|Short title||Drug for colorectal cancer|
|Effective start/end date||15/08/17 → 14/08/19|
- United States Department of Defense (DoD): AUD315,413.00